Biotalys N.V.
BTLS.BR
Euronext Brussels3.04
EUR
- -
- -
Biotalys N.V.
BTLS.BR
(Euronext Brussels)
Recent
price
3.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biotalys N.V. (Euronext Brussels: BTLS.BR) develops protein-based biocontrol solutions for sustainable crop protection as an agricultural technology company targeting pests and diseases across the food value chain from soil to plate. The company offers a pipeline of products based on its proprietary AGROBODY™ technology platform, including the lead biofungicide EVOCA™ against botrytis and powdery mildew in fruits and vegetables, which received U.S. EPA regulatory approval in 2025 and awaits EU approval; EVOCA NG, an enhanced next-generation formulation with planned U.S. registration in 2028-29; BioFun-6 targeting additional fungal pathogens; and BioFun-8, a new biofungicide program launched in October 2024 against Alternaria leaf spot in fruits, vegetables, and potatoes, addressing a USD 1.1 billion market opportunity; as well as earlier-stage bioinsecticides and biobactericides. Biotalys serves pre- and post-harvest markets for growers seeking alternatives to chemical pesticides with novel modes of action, low environmental impact, and favorable safety profiles. Founded in 2013 as a spin-off from VIB (Flanders Institute for Biotechnology), the company maintains headquarters in Ghent, Belgium, with a North American subsidiary office in North Carolina, USA, and recently opened expanded R&D facilities there comprising 1,800 square meters of laboratory space. Recent developments include a EUR 15 million private placement in October 2024 with new investor ASR Vermogensbeheer and existing backers Ackermans & van Haaren and AIF to fund regulatory processes for EVOCA™ and EVOCA NG, field trials for BioFun-6, and pipeline expansion; addition of BioFun-8 to the R&D pipeline in 2024; a strategic partnership announced in May 2025 with AgroFresh Solutions, Inc. for post-harvest biological solutions; and ongoing academic collaborations for programs like BioFun-4.